Niagen Bioscience, Inc. — Director's Dealing 2021

Mar 15, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: ChromaDex Corp. (CDXC)
CIK: 0001386570
Period of Report: 2021-03-12

Reporting Person: Harrington Lisa Hatton (N/A)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Options (right to buy)	$4.85	2030-12-02	Common Stock (250000)		Direct

Footnotes

F1: Options vest 33% on December 3, 2021 and thereafter 1/36th vest each month.